

# Potito Rosario Scalzulli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10194072/publications.pdf>

Version: 2024-02-01

47  
papers

1,113  
citations

430874

18  
h-index

414414

32  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1581  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	1.7	10
2	Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 102, 26.	1.5	1
3	Leukemia-associated immunophenotypes subdivided in categories of specificity improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 216-225.	1.5	19
4	Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. <i>Blood Reviews</i> , 2020, 41, 100647.	5.7	20
5	Brentuximab-related apoptotic colopathy. <i>Pathology</i> , 2020, 52, 483-484.	0.6	6
6	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020, 104, 581-587.	2.2	10
7	Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 195-200.	1.5	11
8	Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 42-48.	1.3	12
9	Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2018, 97, 1817-1824.	1.8	9
10	Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 174-179.	2.1	19
11	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	1.6	94
12	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.8	13
13	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	2.5	16
14	How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2016, 128, 5472-5472.	1.4	0
15	Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL. <i>Blood</i> , 2015, 126, 1999-1999.	1.4	4
16	Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma. <i>Blood</i> , 2015, 126, 4305-4305.	1.4	0
17	Patients with Unexplained Thrombosis Require a Prompt Investigation to Search a Chronic Myeloproliferative Neoplasm (MPN), Even If Platelet Count Is <600x10 <sup>9</sup> /L. Analysis on 129 Patients from Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2015, 126, 5181-5181.	1.4	0
18	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2015, 126, 4071-4071.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilmâ€™s tumor 1 levels. <i>Annals of Hematology</i> , 2014, 93, 1149-57.	1.8	26
20	Plerixafor onâ€demand combined with chemotherapy and granulocyte colonyâ€stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. <i>British Journal of Haematology</i> , 2014, 164, 113-123.	2.5	55
21	Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT). <i>Blood</i> , 2014, 124, 3196-3196.	1.4	0
22	Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen). <i>Blood</i> , 2012, 120, 5032-5032.	1.4	4
23	Non-pegylated liposomal doxorubicin (Myocetâ€™) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1222-1229.	1.3	26
24	Combination Treatment of Flag with Non-Pegylated Liposomal Doxorubicin (MYOCETâ€™) in Elderly Patients with Acute Myeloid Leukemia: A Single Center Experience. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 703-709.	2.1	9
25	Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. <i>Leukemia Research</i> , 2011, 35, 1557-1563.	0.8	32
26	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2010, 116, 1973-1973.	1.4	2
27	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 233-238.	3.4	85
28	Rituximab to treat chronic lymphoproliferative disorderâ€™associated pure red cell aplasia. <i>European Journal of Haematology</i> , 2009, 82, 235-239.	2.2	22
29	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640.	4.1	75
30	Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias. <i>American Journal of Hematology</i> , 2008, 83, 686-687.	4.1	3
31	Peg-filgrastim versus filgrastim after autologous stem cell transplantation: Case-control study in patients with multiple myeloma and review of the literature. <i>Leukemia Research</i> , 2007, 31, 1487-1493.	0.8	14
32	Intermediate-Dose Melphalan (100 mg/m2)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
33	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.8	17
34	Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2005, 128, 204-209.	2.5	93
35	Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. <i>Lancet, The</i> , 2005, 366, 318-320.	13.7	57
36	Heterogeneity of Response to Imatinib-Mesylate (Gleevec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis. <i>Leukemia and Lymphoma</i> , 2004, 45, 1219-1222.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplantation, 2004, 33, 131-132.	2.4	36
38	Calcitriol Increases Burst-Forming Unit-Erythroid Proliferation in Chronic Renal Failure. Nephron Clinical Practice, 2003, 95, c121-c127.	2.3	86
39	Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial. Leukemia and Lymphoma, 2003, 44, 1545-1548.	1.3	43
40	Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial. Leukemia and Lymphoma, 2003, 44, 1545-1548.	1.3	35
41	Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure. Nephrology Dialysis Transplantation, 1999, 14, 1171-1175.	0.7	8
42	Circulating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield. Bone Marrow Transplantation, 1998, 22, 215-216.	2.4	4
43	Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. , 1998, 58, 255-262.		24
44	Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. Nephrology Dialysis Transplantation, 1998, 13, 1194-1199.	0.7	5
45	Clinical results of recombinant erythropoietin in transfusionâ€dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. European Journal of Haematology, 1997, 58, 314-319.	2.2	45
46	Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. British Journal of Haematology, 1995, 90, 125-130.	2.5	16
47	RECOMBINANT ERYTHROPOIETIN FOR MYELOYDYSPLASTIC SYNDROMES. British Journal of Haematology, 1995, 91, 256-257.	2.5	4